Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.56 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 17/20 | 0.54 |
| ▸ | FLT3 | P36888 | 8/20 | 0.54 |
| ▸ | KIT | P10721 | 8/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | FLT1 | P17948 | 4/20 | 0.45 |
| ▸ | LCK | P06239 | 4/20 | 0.45 |
| ▸ | RET | P07949 | 4/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.45 |
| ▸ | BLK | P51451 | 4/20 | 0.45 |
| ▸ | MAP4K5 | Q9Y4K4 | 4/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.45 |
| ▸ | SYK | P43405 | 3/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.45 |
| ▸ | LYN | P07948 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5802029 | 0.85 | ABL1 (0.51) | KDRFLT3RIPK1LCKBLK | |
| SCHEMBL6431200 | 0.83 | AURKB (0.52) | AURKAAURKBIKBKEKDRFLT3 | |
| SCHEMBL15978893 | 0.80 | RET (0.62) | AURKAAURKBIKBKEKDRFLT3 | |
| SCHEMBL5801898 | 0.79 | SRC (0.54) | KDRABL1SRCPIK3CDEGFR | |
| SCHEMBL5804211 | 0.78 | AURKB (0.59) | AURKAAURKBIKBKEKDRFLT3 | |
| SCHEMBL5823907 | 0.78 | AURKA (0.58) | AURKAAURKBIKBKEKDRFLT3 | |
| SCHEMBL6437239 | 0.77 | KDR (0.66) | AURKAAURKBIKBKEKDRFLT3 | |
| SCHEMBL5801797 | 0.77 | AURKA (0.57) | AURKAAURKBIKBKEKDRFLT3 | |
| SCHEMBL6434464 | 0.76 | LCK (0.56) | AURKAAURKBIKBKEKDRFLT3 | |
| SCHEMBL5804562 | 0.76 | AURKA (0.56) | AURKAAURKBIKBKEKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | AURKA 2294/4885AURKB 1952/4885IKBKE 1020/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | AURKA 443/4885AURKB 481/4885IKBKE 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.